Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Patched-1 receptor (PTCH1) is a 12-pass transmembrane receptor that acts as the primary receptor for Sonic Hedgehog (SHH) and other Hedgehog ligands. PTCH1 functions as a tumor suppressor by inhibiting the GPCR-like signaling protein Smoothened (SMO) in the absence of Hedgehog ligands. Upon binding of Hedgehog ligands to PTCH1, this inhibition is relieved, allowing propagation of Hedgehog signaling, which influences critical processes during embryogenesis, cell proliferation, tissue patterning, and tumorigenesis. Mutations in PTCH1 can cause constitutive activation of the Hedgehog pathway, contributing to developmental disorders and various cancers such as basal cell carcinoma and medulloblastoma. PTCH1 is a key therapeutic target in Hedgehog pathway-driven tumors, with clinical focus on indirectly targeting its pathway through SMO inhibitors.
Inhibitors relieve PTCH1-mediated suppression of Smoothened, thus activating Hedgehog pathway signaling. Some drugs (like vismodegib/sonidegib) act on Smoothened to modulate effects downstream of PTCH1 loss or mutation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Patched-1 receptor (PTCH1).